A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer

BACKGROUND: To evaluate the efficacy of cetuximab combined with modified FOLFIRI (mFOLFIRI) as a second-line treatment in metastatic gastric cancer patients and to identify potential biomarkers of clinical outcomes. METHODS: All 61 patients received an initial intravenous (IV) dose of cetuximab (400...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xin, Guo, Weijian, Zhang, Wen, Yin, Jiliang, Zhang, Jun, Zhu, Xiaodong, Liu, Tianshu, Chen, Zhiyu, Wang, Biyun, Chang, Jianhua, Lv, Fangfang, Hong, Xiaonan, Wang, Huijie, Wang, Jialei, Zhao, Xinmin, Wu, Xianghua, Li, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348753/
https://www.ncbi.nlm.nih.gov/pubmed/28288572
http://dx.doi.org/10.1186/s12885-017-3174-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348753/
https://www.ncbi.nlm.nih.gov/pubmed/28288572
http://dx.doi.org/10.1186/s12885-017-3174-z

Ejemplares similares